-
1
-
-
0034665138
-
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylami-nopyrimidine class
-
Kilic T, Alberta JA, Zdunek PR et al (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylami-nopyrimidine class. Cancer Res 60(18):5143-5150
-
(2000)
Cancer Res
, vol.60
, Issue.18
, pp. 5143-5150
-
-
Kilic, T.1
Alberta, J.A.2
Zdunek, P.R.3
-
2
-
-
33644830094
-
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
-
Reardon DA, Egorin MJ, Quinn JA et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23(36):9359-9368
-
(2005)
J Clin Oncol
, vol.23
, Issue.36
, pp. 9359-9368
-
-
Reardon, D.A.1
Egorin, M.J.2
Quinn, J.A.3
-
3
-
-
34247476830
-
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
-
DOI 10.1007/s11060-006-9302-2
-
Desjardins A, Quinn JA, Vredenburgh JJ et al (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83(1):53-60 (Pubitemid 46647165)
-
(2007)
Journal of Neuro-Oncology
, vol.83
, Issue.1
, pp. 53-60
-
-
Desjardins, A.1
Quinn, J.A.2
Vredenburgh, J.J.3
Sathornsumetee, S.4
Friedman, A.H.5
Herndon, J.E.6
McLendon, R.E.7
Provenzale, J.M.8
Rich, J.N.9
Sampson, J.H.10
Gururangan, S.11
Dowell, J.M.12
Salvado, A.13
Friedman, H.S.14
Reardon, D.A.15
-
4
-
-
33748376520
-
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
-
DOI 10.1158/1078-0432.CCR-06-0773
-
Wen PY, Yung WK, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899-4907 (Pubitemid 44338577)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.16
, pp. 4899-4907
-
-
Wen, P.Y.1
Yung, W.K.A.2
Lamborn, K.R.3
Dahia, P.L.4
Wang, Y.5
Peng, B.6
Abrey, L.E.7
Raizer, J.8
Cloughesy, T.F.9
Fink, K.10
Gilbert, M.11
Chang, S.12
Junck, L.13
Schiff, D.14
Lieberman, F.15
Fine, H.A.16
Mehta, M.17
Robins, H.I.18
DeAngelis, L.M.19
Groves, M.D.20
Puduvalli, V.K.21
Levin, V.22
Conrad, C.23
Maher, E.A.24
Aldape, K.25
Hayes, M.26
Letvak, L.27
Egorin, M.J.28
Capdeville, R.29
Kaplan, R.30
Murgo, A.J.31
Stiles, C.32
Prados, M.D.33
more..
-
5
-
-
53749096014
-
Phase II study of imatinib in patients with recurrent gliomas of varying histologies: A European Organization for Research and Treatment of Cancer Brain Tumor Group Study
-
Raymond E, Brandes AA, Dittrich C et al (2008) Phase II study of imatinib in patients with recurrent gliomas of varying histologies: a European Organization for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26(28):4659-4665
-
(2008)
J Clin Oncol
, vol.26
, Issue.28
, pp. 4659-4665
-
-
Raymond, E.1
Brandes, A.A.2
Dittrich, C.3
-
6
-
-
1342330066
-
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)
-
DOI 10.1080/10428190310001625728
-
Leis JF, Stepan DE, Curtin PT et al (2004) Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45(4):695-698 (Pubitemid 38256028)
-
(2004)
Leukemia and Lymphoma
, vol.45
, Issue.4
, pp. 695-698
-
-
Leis, J.F.1
Stepan, D.E.2
Curtin, P.T.3
Ford, J.M.4
Peng, B.5
Schubach, S.6
Druker, B.J.7
Maziarz, R.T.8
-
7
-
-
12144290456
-
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
-
DOI 10.1007/s00280-003-0741-6
-
le Coutre P, Kreuzer KA, Pursche S et al (2004) Pharmacoki-netics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53(4):313-323 (Pubitemid 38392356)
-
(2004)
Cancer Chemotherapy and Pharmacology
, vol.53
, Issue.4
, pp. 313-323
-
-
Le Coutre, P.1
Kreuzer, K.-A.2
Pursche, S.3
Bonin, M.V.4
Leopold, T.5
Baskaynak, G.6
Dorken, B.7
Ehninger, G.8
Ottmann, O.9
Jenke, A.10
Bornhauser, M.11
Schleyer, E.12
-
8
-
-
11144355075
-
Plasma and cerebro-spinal fluid pharmacokinetics of imatinib after administration to nonhuman primates
-
DOI 10.1158/1078-0432.CCR-03-0155
-
Neville K, Parise RA, Thompson P (2004) Plasma and cerebro-spinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 10(7):2525-2529 (Pubitemid 38445714)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.7
, pp. 2525-2529
-
-
Neville, K.1
Parise, R.A.2
Thompson, P.3
Aleksic, A.4
Egorin, M.J.5
Balis, F.M.6
McGuffey, L.7
McCully, C.8
Berg, S.L.9
Blaney, S.M.10
-
9
-
-
0037419496
-
Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma
-
DOI 10.1016/S1570-0232(02)00659-1, PII S1570023202006591
-
Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 783(1):231-236 (Pubitemid 35351650)
-
(2003)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.783
, Issue.1
, pp. 231-236
-
-
Parise, R.A.1
Ramanathan, R.K.2
Zamboni, W.C.3
Egorin, M.J.4
-
10
-
-
34548068014
-
Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat
-
Akingbemi BT, Braden TD, Kemppainen BW et al (2007) Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat. Endocrinology 148(9):4475-4488
-
(2007)
Endocrinology
, vol.148
, Issue.9
, pp. 4475-4488
-
-
Akingbemi, B.T.1
Braden, T.D.2
Kemppainen, B.W.3
-
11
-
-
26444621412
-
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series
-
DOI 10.1093/annonc/mdi317
-
Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16(10):1702-1708 (Pubitemid 41510147)
-
(2005)
Annals of Oncology
, vol.16
, Issue.10
, pp. 1702-1708
-
-
Dresemann, G.1
-
12
-
-
33751521850
-
Influence of hydroxyurea on imatinib mesylate (Gleevec) transport at the mouse blood-brain barrier
-
Bihorel S, Camenisch G, Gross G, Lemaire M, Scherrmann JM (2006) Influence of hydroxyurea on imatinib mesylate (Gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos 34(12):1945-1949
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.12
, pp. 1945-1949
-
-
Bihorel, S.1
Camenisch, G.2
Gross, G.3
Lemaire, M.4
Scherrmann, J.M.5
-
13
-
-
34548278289
-
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier
-
DOI 10.1111/j.1471-4159.2007.04808.x
-
Bihorel S, Camenisch G, Lemaire M, Scherrmann JM (2007) Influence of breast cancer resistance protein (Abcg2) and p-gly-coprotein (Abcb1a) on the transport of imatinib mesylate (Glee-vec) across the mouse blood-brain barrier. J Neurochem 102(6):1749-1757 (Pubitemid 47329285)
-
(2007)
Journal of Neurochemistry
, vol.102
, Issue.6
, pp. 1749-1757
-
-
Bihorel, S.1
Camenisch, G.2
Lemaire, M.3
Scherrmann, J.-M.4
-
14
-
-
0344520475
-
Distribution of STI-571 to the brain is limited by P-glycoprotein- mediated efflux
-
DOI 10.1124/jpet.102.045260
-
Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304(3):1085-1092 (Pubitemid 36254421)
-
(2003)
Journal of Pharmacology and Experimental Therapeutics
, vol.304
, Issue.3
, pp. 1085-1092
-
-
Dai, H.1
Marbach, P.2
Lemaire, M.3
Hayes, M.4
Elmquist, W.F.5
-
15
-
-
53749086477
-
Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib
-
Abstract
-
Razis E, Selviaridis P, Fletcher J et al (2007) Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib. J Clin Oncol 25(18S):2023 (Abstract
-
(2007)
J Clin Oncol
, vol.25
, Issue.18 S
-
-
Razis, E.1
Selviaridis, P.2
Fletcher, J.3
-
16
-
-
72049088625
-
Tumor sequestration of lapatinib (NABTC 04-01)
-
Kuhn J, Robins HI, Mehta M et al (2008) Tumor sequestration of lapatinib (NABTC 04-01). Neuro Oncol 10(5):783 (Abstract
-
(2008)
Neuro Oncol
, vol.10
, Issue.5
, pp. 783
-
-
Kuhn, J.1
Robins, H.I.2
Mehta, M.3
-
17
-
-
27744506881
-
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
-
Lassman AB, Rossi MR, Raizer JJ et al (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11(21):7841-7850
-
(2005)
Clin Cancer Res
, vol.11
, Issue.21
, pp. 7841-7850
-
-
Lassman, A.B.1
Rossi, M.R.2
Raizer, J.J.3
-
18
-
-
37549070324
-
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
-
Kuhn JG, Chang SM, Wen PY et al (2007) Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13(24):7401-7406
-
(2007)
Clin Cancer Res
, vol.13
, Issue.24
, pp. 7401-7406
-
-
Kuhn, J.G.1
Chang, S.M.2
Wen, P.Y.3
-
19
-
-
38849208347
-
Anti-tumor activity of rapamycin in a phase i trial for patients with recurrent PTEN-deficient glioblastoma
-
Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Anti-tumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1):e8
-
(2008)
PLoS Med
, vol.5
, Issue.1
-
-
Cloughesy, T.F.1
Yoshimoto, K.2
Nghiemphu, P.3
|